Obesity Drug Maker Faces Investor Suit Over IPO Disclosures

By Emilie Ruscoe · January 7, 2025, 11:10 PM EST

Biopharmaceutical company BioAge Labs Inc. is facing a proposed class action alleging investors in its initial public offering were hurt by plummeting share prices after the company unexpectedly hit the brakes...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Soto v. BioAge Labs, Inc. et al

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2025

Recent Articles By Emilie

January 06, 2025
Biotech Co. Revance Faces Suit After Tender Offer Weakens
January 02, 2025
Eye Drug Study Blindsided Pharma Co. Investors, Suit Says
December 16, 2024
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
December 13, 2024
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
December 06, 2024
Two Firms To Rep CVS Investors In Benefit Unit Losses Suit
November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim